The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
Open accessAbstract
BACKGROUND: The clinical management of chronic hepatitis B virus (HBV) patients is based exclusively on virological parameters that cannot independently determine in which patients nucleos(t)ide-analogue (NUC) therapy can be safely discontinued. NUCs efficiently suppress viral replication, but do not eliminate HBV. Thus, therapy discontinuation can be associated with virological and biochemical relapse and, consequently, therapy in the majority is life-long. METHODS: Since antiviral immunity is pivotal for HBV control, we investigated potential biomarkers for the safe discontinuation of NUCs within immune profiles of chronic HBV patients by utilizing traditional immunological assays (ELISPOT, flow cytometry) in conjunction with analyses of global non-antigen-specific immune populations (NanoString and CyTOF). Two distinct cohorts of 19 and 27 chronic HBV patients, respectively, were analyzed longitudinally prior to and after discontinuation of 2 different NUC therapy strategies. RESULTS: Absence of hepatic flares following discontinuation of NUC treatment correlated with the presence, during NUC viral suppression, of HBV core and polymerase-specific T cells that were contained within the ex vivo PD-1+ population. CONCLUSIONS: This study identifies the presence of functional HBV-specific T cells as a candidate immunological biomarker for safe therapy discontinuation in chronic HBV patients. Furthermore, the persistent and functional antiviral activity of PD-1+ HBV-specific T cells highlights the potential beneficial role of the expression of T cell exhaustion markers during human chronic viral infection. FUNDING: This work was funded by a Singapore Translational Research Investigator Award (NMRC/STaR/013/2012), the Eradication of HBV TCR Program (NMRC/TCR/014-NUHS/2015), the Singapore Immunology Network, the Wellcome Trust (107389/Z/15/Z), and a Barts and The London Charity (723/1795) grant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Since PD-1 expression is considered the classical hallmark of exhausted T cells (24), our results may appear counterintuitive.”
ResultBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
McKinney, E. F., Lee, J. C., Jayne, D. R. W., Lyons, P. A., & Smith, K. G. C. (2015) · Nature · doi:10.1038/nature14468 · Cited by 685 · cited 2×
“Furthermore, it was recently reported that a transcriptional T cell signature that is linked to CD8+ T cell exhaustion and CD4+ T cell costimulation can predict the outcome of chronic viral infection (12).”
BackgroundIL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection
Pallett, L. J., Davies, J., Colbeck, E. J., Robertson, F., Hansi, N., Easom, N. J. W., Burton, A. R., Stegmann, K. A., Schurich, A., Swadling, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162115 · Cited by 347
Self-citationGill, U. S., Zissimopoulos, A., Al-Shamma, S., Burke, K., McPhail, M. J. W., Barr, D. A., Kallis, Y. N., Marley, R. T. C., Kooner, P., Foster, G. R., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu471 · Cited by 93
Self-citation
Cited by
Immunobiology and pathogenesis of hepatitis B virus infection
Iannacone, M., & Guidotti, L. G. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00549-4 · Cited by 520
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Self-citationHow to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong, G. L. H., Gane, E., & Lok, A. S. F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.024 · Cited by 272
Fine needle aspirates comprehensively sample intrahepatic immunity
Gill, U. S., Pallett, L. J., Thomas, N., Burton, A. R., Patel, A. A., Yona, S., Kennedy, P. T. F., & Maini, M. K. (2019) · Gut · doi:10.1136/gutjnl-2018-317071 · Cited by 87
Self-citationLiu, Z., Li, G., Li, X., Wang, Y., Liao, L., Yang, T., Han, C., Huang, K., Chen, C., Li, X., et al. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106093 · Cited by 7
Metadata
- Authors
- Rivino, L., Le Bert, N., Gill, U. S., Kunasegaran, K., Cheng, Y., Tan, D. Z. M., Becht, E., Hansi, N. K., Foster, G. R., Su, T.-H., Tseng, T.-C., Lim, S. G., Kao, J.-H., Newell, E. W., Kennedy, P. T. F., & Bertoletti, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-01-08
- Volume
- 128
- Issue
- 2
- Pages
- 668-681
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2781766181
- Cited by
- 208
- References
- 6
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.